Overview Performance Dividends Peer Group Options

(AVIR) Atea Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04683R1068

AVIR: Antiviral, COVID-19, Hepatitis, Inhibitors

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of antiviral therapies. Its lead product candidate, AT-527, is an oral antiviral currently in the Phase 3 SUNRISE-3 clinical trial for COVID-19 treatment. The company also develops bemnifosbuvir combined with ruzasvir, in Phase 2 trials for hepatitis C virus (HCV), and a protease inhibitor for COVID-19. Atea has a licensing agreement with MSD International GmbH for Ruzasvir, an NS5A inhibitor for HCV. Incorporated in 2012, Atea is headquartered in Boston, Massachusetts.

The companys pipeline reflects its focus on addressing significant viral infections, leveraging partnerships to enhance its development capabilities. Its strategic approach includes advancing multiple candidates through clinical stages, aiming to provide innovative solutions in the antiviral space.

Based on the provided data, here is a 3-month forecast for Atea Pharmaceuticals, Inc. (NASDAQ:AVIR): The stock is expected to trade within a narrow range, potentially between $2.90 and $3.15 over the next three months. This forecast considers the stocks recent price action, with the last price at $3.03, slightly below the 20-day SMA of $3.07 but above the 50-day SMA of $3.17 and 200-day SMA of $3.44. The Average True Range (ATR) of 0.13 indicates low volatility, suggesting minimal price fluctuations. From a fundamental perspective, Ateas market cap of $258.46M reflects its position as a small-cap biotech company. The absence of P/E and forward P/E ratios suggests the company is currently unprofitable, which is common in clinical-stage biopharmas. The price-to-book (P/B) ratio of 0.56 indicates that the stock is undervalued relative to its book value, which may attract value investors. The price-to-sales (P/S) ratio of 1.90 is moderate, considering the companys pre-revenue stage. The negative return on equity (RoE) of -37.95% highlights the companys focus on reinvesting capital into its pipeline rather than generating profits. The 3-month forecast suggests that AVIR may experience sideways trading with potential upside driven by positive clinical trial results or downside risks from broader market conditions affecting biotechnology stocks. Investors should monitor progress in the SUNRISE-3 trial and any updates on the bemnifosbuvir/ruzasvir combination for HCV, as these could be catalysts for price movement.

Additional Sources for AVIR Stock

News: Wall Street Journal Benzinga Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

AVIR Stock Overview

Market Cap in USD 246m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2020-10-30

AVIR Stock Ratings

Growth Rating -87.7
Fundamental -49.5
Dividend Rating 0.0
Rel. Strength -26.8
Analysts 3.33/5
Fair Price Momentum 1.68 USD
Fair Price DCF -

AVIR Dividends

No Dividends Paid

AVIR Growth Ratios

Growth Correlation 3m -59.8%
Growth Correlation 12m -83.2%
Growth Correlation 5y -90%
CAGR 5y -41.15%
CAGR/Max DD 5y -0.42
Sharpe Ratio 12m -1.82
Alpha -38.85
Beta 0.757
Volatility 49.25%
Current Volume 408.2k
Average Volume 20d 415.1k
What is the price of AVIR stocks?
As of May 09, 2025, the stock is trading at USD 2.76 with a total of 408,236 shares traded.
Over the past week, the price has changed by -7.69%, over one month by +4.15%, over three months by -9.21% and over the past year by -29.77%.
Is Atea Pharmaceuticals a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Atea Pharmaceuticals (NASDAQ:AVIR) is currently (May 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -49.51 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AVIR as of May 2025 is 1.68. This means that AVIR is currently overvalued and has a potential downside of -39.13%.
Is AVIR a buy, sell or hold?
Atea Pharmaceuticals has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold AVIR.
  • Strong Buy: 1
  • Buy: 0
  • Hold: 1
  • Sell: 1
  • Strong Sell: 0
What are the forecast for AVIR stock price target?
According to ValueRays Forecast Model, AVIR Atea Pharmaceuticals will be worth about 1.9 in May 2026. The stock is currently trading at 2.76. This means that the stock has a potential downside of -31.52%.
Issuer Forecast Upside
Wallstreet Target Price 6.5 135.5%
Analysts Target Price 6.5 135.5%
ValueRay Target Price 1.9 -31.5%